Cowen started coverage on shares of Legend Biotech (NASDAQ:PLRX) in a research report report published on Monday, BenzingaRatingsTable reports. The brokerage issued an outperform rating on the stock.
Other equities analysts have also issued research reports about the company. Citigroup began coverage on Legend Biotech in a research report on Monday. They issued a buy rating and a $40.00 price target for the company. Piper Sandler assumed coverage on Legend Biotech in a research report on Monday. They issued an overweight rating and a $50.00 price target for the company. Finally, Needham & Company LLC assumed coverage on Legend Biotech in a research note on Monday. They issued a buy rating and a $40.00 price objective for the company.
Shares of PLRX stock opened at $29.53 on Monday. Legend Biotech has a 1-year low of $21.05 and a 1-year high of $35.63.
Pliant Therapeutics, Inc, a biotechnology company, discovers, develops, and commercializes treatments for fibrotic diseases. The company focuses on tissue-specific integrin modulation and EMT inhibition fibrosis diseases in lungs, liver, muscle, kidney, skin, heart, and the gastrointestinal tract. Its pipeline includes PLN-74809, an inhibitor of aVß1/aVß6 for idiopathic pulmonary fibrosis and primary sclerosing cholangitis; and PLN-1474, an inhibitor of TGF-ß activation by the integrin aVß1 for the treatment of end-stage liver fibrosis in NASH.
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.